Clinical Trials
16 trialsNCT07007312 2026-05-12
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Phase 3 Recruiting
NCT06001788 2026-04-14
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
NCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
NCT07441967 2026-03-02
The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02038777 2025-02-26
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Pfizer
Phase 1 Completed
NCT05476770 2024-12-06
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Recruiting
NCT05536154 2024-03-19
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase NA Unknown
NCT05510089 2023-10-10
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase NA Unknown
NCT03135028 2020-03-06
Japanese AML
Gilead Sciences
Phase 1 Terminated
NCT00439556 2019-09-10
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02676323 2018-11-14
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
Phase 1 Terminated
NCT02718755 2018-06-26
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01621477 2017-02-20
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00429416 2016-11-29
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Thomas Jefferson University
Phase 1/2 Completed
NCT00270881 2012-04-06
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies
Keio University
Phase 1/2 Completed